The REQUITE project is a consortium drawn from some of the leading research institutes around Europe and the United States.


University of Manchester

The University of Manchester is the largest single-site university in the UK. It has a student population of >37,000. Twenty-five Nobel Prize winners have worked or studied at the university. Four Nobel laureates are currently among its staff – more than any other British university. It ranked 41st in the world, eighth in Europe and fifth in the UK in the 2013 Shanghai Jiao Tong World Ranking. The Centre for Integrated Genomic Medical Research (CIGMR) is a unit within the Centre for Epidemiology at the University of Manchester. CIGMR was established by Prof Bill Ollier shortly after the completion of the Human Genome Project in order to progress the delivery of health benefits via genomic and other biomarkers. Its initial focus was in genetic epidemiology. CIGMR recognised that constructing appropriate research infrastructure is essential to this mission and has focussed on experimental platforms for genomics and transcriptomics and for sample management. It has played a major role in the preparation of a European biobanking network and has delivered such networks within Greater Manchester, nationally and internationally, underpinning population cohorts as well as case studies across a wide range of medical specialisms. The work on network development has been led by one of CIGMR's co-Directors, Dr Martin Yuille. The other co-Directors, Prof Ollier, is also the Head of Research and Development for the National Health Service in the City of Salford adjacent to the City of Manchester. CIGMR has developed close links with industry to facilitate the development and adoption of stratified medicine as part of a strategy for delivering improved population health. Read more at To obtain more information about the University of Manchester, go to and for more information about prof. C. West, go to

German Cancer Research Centre (DKFZ), Heidelberg, Germany

DKFZ is the largest biomedical research institute in Germany and a member of the Helmholtz Association of National Research Centers. In over 90 divisions and research groups, our more than 2,500 employees, of which more than 1,000 are scientists, are investigating the mechanisms of cancer, are identifying cancer risk factors and are trying to find strategies to prevent people from getting cancer. They are developing novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. Read more at  

Fundación Pública Galega de Medicina Xenómica (FPGMX)

The Fundación Pública Galega de Medicina Xenómica (FPGMX) is a support organization of the health service of Galicia (NW Spain), comprising near 3 million inhabitants. FPGMX plays an important role in the implementation of activities to promote and protect the health of citizens, ensuring access to genomic tests.

The FPGMX also serves as a tool to support public health care through the use of technological support demanded by almost all medical specialties, given the increasing importance of genomic medicine in the diagnosis and treatment of many diseases, especially in those related to genetics and cancer. FPGMX has all type of genomic facilities for diagnosis and research, including Next Generation Sequencers (SOLID5500, SOLID 4, Ion Torrent and Ion Proton), Sequenom MALDITOF-MS, Affymetrix and AXIOM platforms

The FPGMX 's mission is to promote the development of a competitive genomic medicine in our region and the integration into existing international networks, both in the clinical setting and in the molecular research. To do this, we have the technological and human resources necessary for the effective development of genomic research, establishing programs and quality standards. Our projects and services are possible thanks to the efforts of many professionals working in multidisciplinary teams, composed of geneticists, clinicians, bioinformaticians, biotechnologist, etc .... To obtain more information, go to

National Cancer Institute of Milan

The National Cancer Institute of Milan is a Comprehensive Cancer Center founded in 1928. The INT Unit of Radiation Oncology 1 is directed by Dr. Riccardo Valdagni. It treats patients with breast, genitourinary, gastrointestinal and lung cancer, bone and soft tissue sarcomas, lymphomas, and pediatric cancers with a multidisciplinary approach, following national and international guidelines. The Unit is also proactive in preclinical and translational research and participates in national and international protocols. To obtain more information about the National Cancer Institute of Milan, go to

University Hospitals Leuven/ KU Leuven

The department of Radiation Oncology of the University Hospitals Leuven/ KU Leuven is the largest radiotherapy department of Flanders, Belgium with more than 2200 patients treated each year. It has put strong effort in a multi-disciplinary approach of cancer patients facing the challenge of improving radiation treatment, relying on a modern infrastructure of 5 linear accelerators, 2 simulators (1 CT) and 2 brachytherapy afterloaders. The department is also involved in several clinical research programs focusing on optimization of radiation therapy treatment using biological image guided target delineation, response prediction, prognosis and therapeutic outcome. For more information about the department of Radiation Oncology of the University Hospitals Leuven/ KU Leuven, go to

Institut du Cancer de Montpellier – ICM (Montpellier Cancer Institute)

The ICM is one of the 20 French Comprehensive Cancer Centers (FCCC), which are private, non-profit establishments with 4 missions: patient care, prevention, research and oncology teaching. The FCCC model is based on personalized and innovative global patient management (medical, psychological and social) from detection up through post-treatment follow-up. The innovation in patient management is also an element of the ICM Medical Scientific Project.

The ICM raised over the years at the forefront of the top-performing Comprehensive Cancer Centers’ research for Clinical, fundamental and translational research.

The ICM is part of UNICANCER, a hospital group entirely devoted to fighting cancer; to learn more go to

Mount Sinai Health System

The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care. The seven hospital campuses are Mount Sinai Beth Israel, Mount Sinai Beth Israel Brooklyn, The Mount Sinai Hospital, Mount Sinai Queens, Mount Sinai Roosevelt, Mount Sinai St. Luke’s, and New York Eye and Ear Infirmary of Mount Sinai. The integrated resources and expertise offer patients comprehensive care from birth through geriatrics, including complex cases. The Mount Sinai Health System includes 3,571 beds, 138 operating rooms, 12 ambulatory surgical centers and 45 ambulatory care practices. There are approximately 35,000 employees, including, 6,600 physicians and 2,000 residents and fellows. Each year, there are more than 177,000 inpatient admissions, 2,600,000 outpatient visits to offices and clinics, 500,000 Emergency Department visits and 18,000 babies are born in the Mount Sinai Health System. In addition, the Icahn School of Medicine at Mount Sinai received $323 million in grant funding during 2012.To obtain information about medical care through the Mount Sinai Health System, go to

Ghent University and Ghent University Hospital

“The research program of the Department of Basic Medical Sciences of the Faculty of Medicine and Health Sciences of the Ghent University (Belgium) is focused on translational research topics  in medical applications of fundamental sciences. For more than 10 years  the DNA repair and Radiation Research group of this department  performs studies on radiogenomics in collaboration with the Radiotherapy Department of the Ghent University Hospital. The Radiotherapy Department of the Ghent University Hospital is specialized in intensity-modulated radiation therapy (IMRT) and intensity-modulated arc therapy (IMAT). The results of clinical IMRT trials led to improvement of tumor control and decrease of treatment induced toxicity. Biological-image-guided techniques are investigated for further improving disease control. Clinical implementation of IMRT for breast cancer in prone position is going on.

In the framework of this collaboration between both departments  substantial work has been performed over the years to identify candidate genes and genetic variations associated with clinical radiosensitivity in populations treated with radiotherapy for breast, prostate, head and neck, lung or gynaecological cancer. For this  radiogenomics research sample collection has been per formed also in multicentre settings with different hospitals in Belgium and in collaboration with the MAASTRO clinic of  the Netherlands.

More recently research is focused on prediction models for acute and late effects in radiotherapy patients taking into account the combination of clinical, dosimetric and genetic factors. Advanced statistical techniques as EMLasso have been introduced for selection of variables in multivariate regression prediction models. Up to now special attention has been paid to prediction of oesophagitis and dysphagia as normal tissue complications in lung and head and neck cancer populations. This research is performed in strong collaboration with the Biostat research unit of the Department of Mathematical Modelling, Statistics and Bio-Informatics. Research topics of this research unit  are related to application of nonparametric and semiparametric statistics to high thoughput genomics.” To obtain more information, go to

The Christie NHS Foundation Trust

The Christie NHS Foundation Trust is the largest cancer centre in Europe, treating more than 40,000 patients a year providing radiotherapy and chemotherapy services as well as highly specialist surgery for complex and rare cancers.  Specifically, we treat over 8,000 radiotherapy patients per annum in one of the world's largest radiotherapy departments . We are also the first UK centre to be officially accredited as a comprehensive cancer centre and our cancer research in Manchester is rated the best in the UK. We have a large successful programme of cancer research, and the clinical trials unit has around 400 trials ongoing at any time, making it the largest early phase trials unit in the world. We are part of the Manchester Cancer Research Centre working with The University of Manchester and Cancer Research UK. For more information, please visit:

University of Leicester

The University of Leicester is one of the top 20 universities in the UK and in the top 200 worldwide. The university has a successful and growing programme of cancer research in which it is investing strongly, being a nationally-funded Experimental Cancer Medicine Centre and Cancer Research UK research centre. It has first-rate informatics and database expertise, which has led and supported national and international projects in genotype-phenotype research, systems medicine, and biobanking. There is an active, interdisciplinary network of groups working on radiobiology, covering a diverse range of approaches from clinical trials, genetic studies, animal and cellular model systems to molecular analyses of DNA formation and repair. There is close interaction with the University Hospitals of Leicester. To obtain more information about the University of Leicester, go to

Maastricht Radiation Oncology (MAASTRO Clinic)

MAASTRO Clinic is one of the leading radiotherapy centers in Europe and is embedded in the School GROW (growth, and development - and the Faculty of Health Medicine and Life Sciences at Maastricht University. MAASTRO is an integrated institute combining a radiation oncology centre with facilities for clinical research and research laboratories. MAASTRO Clinic offers state-of-the-art radiotherapy to more than 4000 cancer patients each year from the Mid and South Limburg area in the Netherlands. MAASTRO Clinic publishes more than 70 radiotherapy focused scientific publications annually. To obtain more information about MAASTRO Clinic, go to

Medical Faculty Mannheim of University of Heidelberg

With more than 30 clinics and institutes the University Medical Centre Mannheim offers a broad spectrum of modern diagnostic and therapeutic resources and covers almost all disciplines of clinical medicine. Over 4,500 people, including renowned specialists and 1,200 nurses are working hand in hand to provide best treatment and optimum care for about 66,000 patients a year. Among them are also a lot of patients from abroad. The combination of health care, research and education enables state-of-the-art examination and treatment in Mannheim. To obtain more information, go to

Source BioScience plc (LSE: SBS)

Source BioScience plc is an international laboratory services and products business serving the healthcare and life science research markets. The Healthcare operations provide screening and reference laboratory diagnostic testing for cancer and other diseases in addition to complementary products for serology, diagnostics and sample storage. The LifeSciences division provides gene-based laboratory research support from conceptualisation to implementation, calling upon a wide range of innovative technology platforms and an online catalogue of biomolecular tools including cDNA clones and antibodies. The PharmaBiotech division provides support for drug discovery, from biomarker discovery and clinical trial services through to stability storage and sample archiving under environmentally controlled conditions. A superior quality management system, including GLP, GCP and CPA accreditations, makes the services very attractive for applications in regulatory studies or in a clinical and diagnostic setting. Source BioScience has its headquarters in Nottingham, UK. For more information, see

University of Cambridge

The mission of the University of Cambridge is to contribute to society through the pursuit of education, learning, and research at the highest international levels of excellence. The University’s teaching and research is organised into six schools: Arts and Humanities, Biological Sciences, Clinical Medicine, Humanities and Social Sciences, Physical Sciences, and Technology. The University of Cambridge has more than 18,000 students from all walks of life and all corners of the world, nearly 9,000 staff, 31 Colleges and 150 Departments, Faculties, Schools and other institutions. For more information, see

University of Montpellier

The University of Montpellier is a research-intensive university where education and research cover most of the Scientific and Technological fields. The university counts 9 faculties: Medicine, Pharmacy, Dentistry, Science, Sports, Economy, Economic and Social Administration, Law and Political Science, Education, 3 Institutes of Technology, 3 institutes: Public Administration, Business and Administration, Business and Management and 2 specialised schools: Polytech Montpellier Engineering School and OREME (observatory). The University of Montpellier is one of the oldest universities in Europe. There are 43 839 students and the UM is the 6th largest university in France. For more information, see